安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Immatics
Immatics combines the discovery of cancer targets with T cell receptor development to create Adoptive Cell Therapies and TCR Bispecifics
- Pipeline - Immatics
Our Pipeline About PRAME PRAME is a target expressed in more than 50 cancers Immatics is the global leader in precision targeting of PRAME and has the broadest PRAME franchise with the most PRAME indications and modalities
- Careers - Immatics
Immatics’ fundamental purpose is to apply its technology and drug development efforts toward improving the outcomes for patients with cancer through the exciting advances of using the immune system to fight the disease
- ACTengine® IMA203 | Immatics
IMA203-101 (NCT03686124) is a Phase 1 first-in-human dose-escalating clinical trial evaluating the safety, tolerability, and initial signs of clinical and biological efficacy of Immatics’ ACTengine ® cell therapy IMA203 in patients with recurrent and or refractory solid tumors
- About - Immatics
Today, Immatics is the global leader in the precision targeting of PRAME, a target expressed in more than 50 cancers, and has the broadest PRAME franchise with the most PRAME indications and modalities
- Technologies | Immatics
Immatics has brought together its technology platforms XPRESIDENT ®, XCEPTOR ®, and XCUBE ™ within one interdisciplinary team, the Immatics DISCOVERY UNIT The team is focused on all early-stage preclinical pipeline and collaboration programs
- Clinical Trials | Immatics
Immatics is the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers The Company’s robust clinical pipeline forms the broadest PRAME franchise with the most PRAME indications and modalities
- Inside Immatics | Immatics
Business line: +1 346 204-5400 Fax line: +1 346 204-5931 E-Mail: info@immatics com Immatics Biotechnologies GmbH Machtlfinger Str 7 81379 Munich Germany
|
|
|